The Clinical Protocol and Data Management Shared Resource (known at Stanford as the """"""""Cancer Clinical Trials Office"""""""" or CCTO) provides administrative, research, and educational services to Cancer Center investigators conducting clinical trials. The goals of the Clinical Protocol and Data Management Shared Resource are to: (1) Facilitate clinical trials and translational research by providing administrative support to all Cancer Center investigators; (2) Enhance and facilitate data collection and reporting of clinical cancer research; (3) Provide programs to contribute to quality assurance of performance and the ongoing education of Cancer Center Clinical Research Personnel; (4) Coordinate outreach efforts in the community (Northern California) to increase clinical trials awareness and accrual; and (5) Promote interdisciplinary collaborations and translational medical research. Prior to 2003, Stanford did not have an institutionally supported Cancer Clinical Trials Office. With the decision to apply for NCI-designation as a Cancer Center, the School of Medicine and Stanford Hospital committed funding to the development of a centralized Cancer Clinical Trials Office. The Facility Director was hired in June 2003. The funding for Fiscal Year 2004 was $750,000 allowing the hiring of a core staff of 6 FTE's. In Fiscal Year 2005, Lucile Packard Children's Hospital added its support to this effort. Funding from the three institutional sources totaled $1,400,000 allowing growth to 14 FTE's by August 2005. A small expansion is underway for FY 2006 with funding of $1,600,000 allowing growth to 15.5 FTE's. The CCTO organization has grown to meet the centralization, standardization, and reporting requirements of NCI-designation and the service needs of the clinical research staff. Each year services and usage have expanded. We will continue to adjust staffing and service offerings as needed to meet the priorities of the Cancer Center. PERFORMANCE SITE(S) (organization, city, state) Stanford UniverScientific Goals The mission of the Clinical Protocol and Data Management Shared Resource is to: 1. Facilitate clinical trials and translational research by providing centralized administrative support to all Cancer Center investigators. 2. Centralize and standardize data collection and reporting of clinical cancer research. 3. Provide programs to contribute to quality assurance of performance and the ongoing education of Cancer Center Clinical Research Personnel. 4. Coordinate outreach efforts in the community (Northern California) to increase clinical trials awareness and accrual. 5. Promote Interdisciplinary collaborations and translational medical research. The CCTO provides a centralized resource that assists clinical researchers with administrative services in order to facilitate protocol processing thus allowing the researcher to focus on scientific research needs and patient care. Programs of the Clinical Protocol and Data Management Shared Resource serve to increase awareness and accrual to clinical trials as well as to centralize and standardize the quality and efficiencies of conducting clinical trials in compliance with the regulatory, documentation, and oversight requirements. In this document the Protocol and Data Management Shared Resource will be referred to as the Cancer Clinical Trials Office (CCTO).sity, Stanford, CA PHS 398/2590 (Rev. 09/04) Page 847

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-02
Application #
7623560
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
2
Fiscal Year
2008
Total Cost
$180,580
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications